A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors
Darren Sigal, M.D.
This study will test the safety and effectiveness of OBI-3424. OBI-3424 is an investigational study drug given once every three weeks via intravenous (IV) infusion in patients with advanced solid tumor cancer. This is the first study using OBI-3424 in humans.
Be 18 years of age or older.
Be ambulatory and able to carry out work of a light or sedentary nature. For example, must be capable of performing light housework or office work.
Have tumor tissue collected from a previous or new biopsy to be submitted for eligibility analysis
Patients must not:
Be pregnant or nursing.
Have hepatocellular carcinoma.
Have a history of symptomatic brain disease.
Have had prior radiotherapy to more than 25% of the bone marrow.
All physician visits and study treatments will occur at Scripps Clinic Torrey Pines (Geisel Pavilion).
Participation in the study will last for up to 2 years.
Search for NCT03592264 on https://clinicaltrials.gov/ for additional information.